Evaluation of immune profiles at day 100 in patients who went on to develop late aGVHD or cGVHD. Volcano plots showing significant markers that meet all 3 criteria of a (1) P ≤ .05 (y-axis), (2) ROC AUC of ≥0.60 (circle, ≥0.60; cross, <0.6), and (3) effect ratio ≥1.3 or ≤0.75 (x-axis). The subfigures correspond to (A) cGVHD compared with no-cGVHD controls; (B) late aGVHD compared with no-cGVHD controls, and (C) cGVHD compared with late aGVHD. Cell population are identified by color, with dark blue representing B cells, orange myeloid populations, yellow NK cells, purple NK_reg cells, green T cells, light blue T_reg cells, and dark red plasma cytokines. We note the following clinical variables were modeled as confounding factors in the logistic regression model: (1) prophylaxis or treatment with either alemtuzumab or ATG, (2) prophylaxis or treatment with rituximab, (3) recipient age, (4) the use of a peripheral blood donor product or not, and (5) whether the donor was HLA identical or not.